ERBB2 and ovarian carcinoma: We established a HER-2+ SK-OV-3 ovarian cancer mouse model, and evaluated the therapeutic effect of Pertuzumab-bound armored-T cells by administering 2×106 armored-T cells and Pertuzumab for four consecutive weeks.(Figure 6A).